Results of shareholder votes disclosed under 8-K Item 5.07.
Ladder Capital Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-06-04 meeting.
“2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026: VOTES FOR VOTES AGAINST ABSTENTIONS 104,254,220 609,801 176,543”
Ladder Capital Corp shareholders approved Re-election of Brian Harris and Mark Alexander as Class III Directors at the 2026-06-04 meeting.
“1. The re-election of Brian Harris and Mark Alexander to the Board of Directors as Class III Directors: DIRECTOR NOMINEE VOTES FOR VOTES WITHHELD BROKER NON-VOTES Brian Harris 62,166,495 18,114,825 24,759,244 Mark Alexander 39,455,734 40,825,586 24,759,244”
Mountain Lake Acquisition Corp. shareholders approved Approve removal of blank check company provisions at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
Mountain Lake Acquisition Corp. shareholders approved Approve unclassified board at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
Mountain Lake Acquisition Corp. shareholders approved Approve size and composition of board of directors at the 2026-06-04 meeting.
“For Against Abstain 27,080,981 401,148 401,148 Proposal D The first amended and restated certificate of”
Mountain Lake Acquisition Corp. shareholders approved Approve authorized capital stock of Pubco at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
Mountain Lake Acquisition Corp. shareholders approved Approve domestication from Cayman Islands to Delaware at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
Mountain Lake Acquisition Corp. shareholders approved Approve MLAC merger at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
Mountain Lake Acquisition Corp. shareholders approved Approve business combination agreement at the 2026-06-04 meeting.
“For Against Abstain 27,081,231 400,898 4,598 1 Proposal 2 - The Merger Proposal - To approve and authorize, by a special resolution, the MLAC Merger.”
AppLovin Corp shareholders rejected Stockholder proposal regarding disclosure of voting results by class of shares at the 2026-06-03 meeting.
“Proposal Five: Stockholder Proposal Regarding Disclosure of Voting Results by Class of Shares The Company’s stockholders did not approve a stockholder proposal regarding disclosure of voting results by class of shares, with voting results as follows: For Against Abstain Broker Non-Votes 119,127,022 696,868,093 305,953 39,487,638”
AppLovin Corp shareholders approved Amendment to Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by Delaware law at the 2026-06-03 meeting.
“Proposal Four: Amendment to the Company’s Amended and Restated Certificate of Incorporation to Provide for Officer Exculpation as Permitted by Delaware Law The Company’s stockholders voted to approve an amendment to the Company’s amended and restated certificate of incorporation to provide for officer exculpation as permitted by Delaware law, with voting results as follows: For Against Abstain Broker Non-Votes 735,785,832 80,423,671 91,565 39,487,638”
AppLovin Corp shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-03 meeting.
“Proposal Three: Advisory Vote on Compensation of Named Executive Officers The Company’s stockholders voted to approve on an advisory basis, the compensation of the Company’s named executive officers, with voting results as follows: For Against Abstain Broker Non-Votes 752,959,150 63,070,373 271,545 39,487,638”
AppLovin Corp shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders voted to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, with voting results as follows: For Against Abstain Broker Non-Votes 853,713,514 2,003,724 71,468 0”
AppLovin Corp shareholders approved Election of nine directors to serve until the 2027 annual meeting at the 2026-06-03 meeting.
“Proposal One: Election of Directors The Company’s stockholders voted to elect nine directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, with voting results as follows: Nominee For Withhold Broker Non-Votes Adam Foroughi 789,659,577 26,641,491 39,487,638 Craig Billings 787,450,426 28,850,642 39,487,638 Herald Chen 785,822,622 30,478,446 39,487,638 Margaret Georgiadis 751,666,493 64,634,575 39,487,638 Barbara Messing 781,466,244 34,834,824 39,487,638 Todd Morgenfeld 809,812,856 6,488,212 39,487,638 Victoria Valenzuela 814,003,872 2,297,196 39,487,638 Eduardo Vivas 780,540,695 35,760,373 39,487,638 Maynard Webb 781,488,849 34,812,219 39,487,638”
NEKTAR THERAPEUTICS shareholders approved Approve non-binding advisory resolution regarding executive compensation at the 2026-06-04 meeting.
“The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
NEKTAR THERAPEUTICS shareholders approved Ratify selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the following votes.”
NEKTAR THERAPEUTICS shareholders approved Approve amendment to the Amended and Restated 2017 Performance Incentive Plan to increase authorized shares by 3,000,000 shares at the 2026-06-04 meeting.
“The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares was approved with the following votes.”
NEKTAR THERAPEUTICS shareholders approved Election of Director Howard W. Robin at the 2026-06-04 meeting.
“The individual listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders.”
Carlyle Group Inc. shareholders approved Non-Binding Vote to Approve Named Executive Officer Compensation ("Say-on-Pay") at the 2026-06-03 meeting.
“Item 4. Non-Binding Vote to Approve Named Executive Officer Compensation ( “ Say-on-Pay ” ) FOR AGAINST ABSTAIN BROKER NON-VOTES 246,902,606 54,984,239 432,800 30,694,352”
Carlyle Group Inc. shareholders approved Approval of The Carlyle Group Inc. Amended and Restated 2012 Equity Incentive Plan at the 2026-06-03 meeting.
“Item 3. Approval of The Carlyle Group Inc. Amended and Restated 2012 Equity Incentive Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 252,707,398 49,426,621 185,626 30,694,352”
Carlyle Group Inc. shareholders approved Ratification of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2026 at the 2026-06-03 meeting.
“Item 2. Ratification of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2026 FOR AGAINST ABSTAIN BROKER NON-VOTES 325,337,355 7,384,983 291,659 —”
Carlyle Group Inc. shareholders approved Election to Our Board of Directors of Thirteen Director Nominees for a One-Year Term at the 2026-06-03 meeting.
“William E. Conway, Jr. 294,669,209 7,650,436 30,694,352 David M. Rubenstein 294,696,355 7,623,290 30,694,352 Daniel A. D ’ Aniello 294,883,924 7,435,721 30,694,352 Harvey M. Schwartz 299,883,948 2,435,697 30,694,352 Afsaneh Beschloss 300,033,486 2,286,159 30,694,352 Sharda Cherwoo 299,762,668 2,556,977 30,694,352 Linda H. Filler 299,512,926 2,806,719 30,694,352 Lawton W. Fitt 288,425,619 13,894,026 30,694,352 James H. Hance, Jr. 294,784,933 7,534,712 30,694,352 Mark S. Ordan 293,285,680 9,033,965 30,694,352 Derica W. Rice 294,488,714 7,830,931 30,694,352 William J. Shaw 294,377,755 7,941,890 30,694,352”
NovoCure Ltd shareholders approved Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan.
“4. Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan . The proposal to approve the Company's Amended and Restated 2024 Omnibus Incentive Plan was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 41,680,622 41,161,139 110,839 10,874,130”
NovoCure Ltd shareholders approved Non-binding advisory vote to approve executive compensation.
“3. Approval of a non-binding advisory vote to approve executive compensation . The proposal to approve executive compensation on a non-binding advisory basis was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 75,392,168 7,422,876 137,556 10,874,130”
NovoCure Ltd shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.
“2. Ratification of Independent Registered Public Accounting Firm . The proposal to approve and ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 was approved as an ordinary resolution based upon the following votes: For Against Abstain 91,436,910 2,337,255 52,565”
NovoCure Ltd shareholders approved Election of Directors.
“1. Election of Directors . The eleven nominees for election to the Company’s Board of Directors were elected as directors to hold office until the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes: For Against Abstain Broker non-votes Asaf Danziger 81,489,609 1,388,512 74,479 10,874,130 William Doyle 80,241,009 2,664,190 47,401 10,874,130 Jeryl Hilleman 81,547,820 1,293,373 111,407 10,874,130 David Hung 80,768,325 2,039,529 144,746 10,874,130 Frank Leonard 82,547,254 356,494 48,852 10,874,130 Kinyip Gabriel Leung 79,455,754 3,370,420 126,426 10,874,130 Martin Madden 81,360,641 1,461,539 130,420 10,874,130 Allyson Ocean 81,178,295 1,666,945 107,360 10,874,130 Timothy Scannell 81,540,531 1,292,301 119,768 10,874,130 Kristin Stafford 81,584,398 1,272,045 96,157 10,874,130 William Vernon 81,349,410 1,483,356 119,834 10,874,130”
Viant Technology Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-04 meeting.
“Proposal Two: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s board of directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 59,901,367 445,419 2,205 0”
Viant Technology Inc. shareholders approved Election of Class II directors to serve until 2029 annual meeting at the 2026-06-04 meeting.
“Proposal One: Election of Directors The Company’s stockholders elected the persons listed below as Class II directors, to serve until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Chris Vanderhook 51,583,984 2,522,872 6,242,135 Brett Wilson 53,364,114 742,742 6,242,135”
Firefly Aerospace Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 118,104,954 240,804 47,931 —”
Firefly Aerospace Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
“Proposal 1: Election of Directors Name of Director Nominee For Withheld Broker Non-Votes Jason Kim 90,751,983 6,123,118 21,518,588 Kevin McAllister 88,953,164 7,921,937 21,518,588”
J.Jill, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending January 30, 2027 at the 2026-06-03 meeting.
“The appointment of Grant Thornton as the Company’s independent registered public accounting firm for the current fiscal year ending January 30, 2027 was ratified by the votes set forth below: For Against Abstentions 12,892,580 956 1,494”
J.Jill, Inc. shareholders approved Election of two Class III directors at the 2026-06-03 meeting.
“On June 3, 2026, J.Jill, Inc. (the “Company”) held its 2026 virtual Annual Meeting.”
Hippo Holdings Inc. shareholders approved Advisory Vote on the Frequency of Advisory Votes on Executive Compensation at the 2026-06-02 meeting.
“The stockholders recommended, on an advisory (non-binding) basis, every one year as the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of such vote were: ONE YEAR TWO YEARS THREE YEARS ABSTAIN BROKER NON-VOTES 11,287,205 83,597 368,480 60,774 5,087,200”
Hippo Holdings Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-02 meeting.
“The stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of such vote were: FOR AGAINST ABSTAIN BROKER NON-VOTES 11,165,305 593,270 41,481 5,087,200”
Hippo Holdings Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.
“The stockholders ratified the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: FOR AGAINST ABSTAIN BROKER NON-VOTES 16,771,055 110,501 5,700 —”
Hippo Holdings Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.
“The stockholders elected the three persons named below as directors of the Company, each to serve until the Annual Meeting of Stockholders to be held in 2029 and until each such director’s respective successor is duly elected and qualified or until each such director’s earlier death, resignation, disqualification or removal. The results of such vote were: FOR WITHHELD BROKER NON-VOTES Lori Dickerson Fouché 9,719,518 2,080,538 5,087,200 Hugh R. Frater 10,998,627 801,429 5,087,200 Richard McCathron 11,274,524 525,532 5,087,200”
Tavia Acquisition Corp. shareholders approved Amend the Company's amended and restated memorandum and articles of association to extend the date by which the Company must consummate an initial business combination from June 5, 2026 to March 5, 2027 at the 2026-06-02 meeting.
“At the Extension Meeting, the Company’s shareholders approved a proposal to amend the Company’s amended and restated memorandum and articles of association (the “Articles”), by way of special resolution, in the form set forth as Annex A to the Proxy Statement (the “Articles Amendment”), to extend the date by which the Company must consummate an initial business combination from June 5, 2026 (the “Previous Termination Date”) to March 5, 2027, or such earlier date as determined by the Company’s board of directors, for a total extension of up to nine months after the Previous Termination Date (the “Articles Amendment Proposal”)”
ZEVRA THERAPEUTICS, INC. shareholders rejected Approve an amendment to the Restated Certificate of Incorporation to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting be elected on an annual basis at the 2026-06-04 meeting.
“Proposal 3 — Vote to Approve an Amendment to the Charter to Declassify the Board: For Against Abstain Broker Non-Votes 32,557,653 1,145,079 16,950 12,606,934”
ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal 2 — Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 45,947,281 234,753 144,582 —”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.
“At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 20, 2026 (File No. 001-36913) (the “Proxy Statement”): (1) to elect Douglas W. Calder and Corey Watton to the Company’s Board as Class II directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified (“Proposal 1”)”
QuantumScape Corp shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-03 meeting.
“Proposal 3 – Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers: Votes For Votes Against Abstentions Broker Non-Votes 559,002,144 8,698,731 2,240,550 156,901,206”
QuantumScape Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“Proposal 2 – Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 720,667,490 4,190,393 1,984,748”
QuantumScape Corp shareholders approved Election of ten directors to serve until the 2027 Annual Meeting of Stockholders at the 2026-06-03 meeting.
“Proposal 1 – Election of ten directors to serve until the 2027 Annual Meeting of Stockholders: Director Votes For Votes Withheld Broker Non-Votes Brad Buss 565,041,367 4,900,058 156,901,206 Jeneanne Hanley 564,833,840 5,107,585 156,901,206 Dr. Gena C. Lovett 532,333,045 37,608,380 156,901,206 Dr. Günther Mendl 567,762,930 2,178,495 156,901,206 Dr. Ross Niebergall 568,235,104 1,706,321 156,901,206 Geoffrey Ribar 568,176,229 1,765,196 156,901,206 Dipender Saluja 538,303,962 31,637,463 156,901,206 Sebastian Schebera 541,114,753 28,826,672 156,901,206 Dennis Segers 567,360,975 2,580,450 156,901,206 Dr. Siva Sivaram 567,736,740 2,204,685 156,901,206”
Excelerate Energy, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-04 meeting.
“3. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved, as set forth below: For Against Abstain Broker Non-Votes 111,948,425 5,289 3,379 –”
Excelerate Energy, Inc. shareholders approved Advisory vote on the compensation of named executive officers (Say-on-Pay) at the 2026-06-04 meeting.
“2. The advisory vote on the compensation of the Company's named executive officers was approved, as set forth below: For Against Abstain Broker Non-Votes 110,046,028 350,240 10,784 1,550,041”
Excelerate Energy, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
“1. Each of the individuals listed below were elected at the 2026 Annual Meeting to serve as Directors of the Company until the Company’s Annual Meeting of Stockholders in 2027 and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification, as set forth below: Director Nominee For Withheld Broker Non-Votes Nisha D. Biswal 102,310,031 8,097,021 1,550,041 Deborah L. Byers 110,120,526 286,526 1,550,041 Paul T. Hanrahan 109,593,453 813,599 1,550,041 Steven M. Kobos 106,401,063 4,005,989 1,550,041 Don P. Millican 106,322,956 4,084,096 1,550,041 Tyler D. Todd 101,563,194 8,843,858 1,550,041 Robert A. Waldo 99,893,842 10,513,210 1,550,041”
UNITEDHEALTH GROUP INC shareholders rejected Shareholder proposal requesting adoption of a policy to require any board chair to be independent at the 2026-06-01 meeting.
“4. Shareholder proposal requesting the adoption of a policy to require any board chair to be independent. The shareholder proposal was not approved based upon the following votes: For Against Abstain Broker Non-Votes % of Votes For* 137,347,215 537,634,392 3,348,847 89,736,263 20.24%”
UNITEDHEALTH GROUP INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
“3. Ratification of the appointment of Deloitte & Touche LLP. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified based upon the following votes: For Against Abstain % of Votes For* 729,713,547 37,552,773 800,397 95.00%”
UNITEDHEALTH GROUP INC shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-01 meeting.
“2. Non-binding advisory vote on executive compensation. The Company’s executive compensation was approved by a non-binding advisory vote based upon the following votes: For Against Abstain Broker Non-Votes % of Votes For* 559,434,838 117,731,618 1,163,998 89,736,263 82.74%”
UNITEDHEALTH GROUP INC shareholders approved Election of nine directors for a one-year term at the 2026-06-01 meeting.
“1. Election of Directors. The nine directors were elected at the Annual Meeting for a one-year term based upon the following votes: Director Nominee For Against Abstain Broker Non-Votes % of Votes For* Charles Baker 606,637,150 69,792,687 1,900,617 89,736,263 89.68% Timothy Flynn 646,534,589 31,180,999 614,866 89,736,263 95.39% Paul Garcia 657,046,651 20,686,201 597,602 89,736,263 96.94% Kristen Gil 670,734,403 7,012,293 583,758 89,736,263 98.96% Scott Gottlieb, M.D. 630,040,056 47,696,583 593,815 89,736,263 92.96% Stephen Hemsley 646,655,805 28,777,298 2,897,351 89,736,263 95.73% F. William McNabb III 658,345,360 19,413,024 572,070 89,736,263 97.13% Valerie Montgomery Rice, M.D. 660,235,862 17,561,570 533,022 89,736,263 97.40% John Noseworthy, M.D. 665,000,847 12,755,561 574,046 89,736,263 98.11%”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.